Thanksgiving means it’s a shortened trading week – and today’s article features two biotech stocks to consider shorting this shortened week based on technical analysis and quantitative ratings. For these two biotech stocks that “look bearish and may present interesting investing opportunities on the short side,” CLICK HERE.
How These 3 Medical Device Stocks Beat Biotech
“When it comes to consistent profitability, long-term growth, large competitive moats, and innovation, medical device companies can provide better returns in the long run” compared to biotech stocks, advises the author of today’s article. He proceeds to highlight three medical device stocks which, while not having generated the massive returns some biotech stocks have this year, have handily beaten the NASDAQ Biotechnology Index over the last five years – and which have upcoming catalysts for growth. For these three medical device stocks, CLICK HERE.
Important News Drops Make These 3 Biotech Stocks To Watch In The Coming Weeks
The three biotech stocks highlighted in today’s article are ones to watch carefully in the coming weeks, advises the author, as important news drops are expected – and in the case of two of the stocks, those news drops are related to the companies’ COVID-19 vaccine candidates. For more on these three biotech stocks to watch throughout the remainder of November, CLICK HERE.
These 3 Companies Could Be Buyout Targets For This Growth-Strapped Biotech
If the biotech titan that’s the focus of today’s article is going to improve its growth prospects, it may have to go acquisition shopping in the next few months – and one of the three companies that the author highlights could be its target, as he notes that all three are acquisitions that “the biotech could easily afford and that would dovetail nicely with its core areas of expertise.” For more on these three potential buyout targets, CLICK HERE.
Higher Highs Ahead For This Hot Biotech?
The clinical-stage biotech highlighted in today’s article, dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders, has been one of the hottest biotech stocks this year. And after a run-up that has generated triple-digit returns, there are a number of factors that could help propel it to even higher highs from here. For more on this stock, CLICK HERE.
3 Stocks To Watch In The Volatility-Haunted Biotech Space
When it comes to finding the best biotech stocks to buy, the author of today’s article acknowledges that it “can be tricky given that volatility often haunts the space.” Nonetheless, he proceeds to highlight three biotech stocks to watch – two of which are working on COVID-19 vaccines while the third may be worth a look even though the company is not producing any COVID-19 related treatments or vaccines. For these three biotech stocks, CLICK HERE.
What Makes This Biotech An Attractive Investment? A Promising Lead Candidate, Broad Pipeline — And More
In making the case for why the biotech featured in today’s article, which is focused on the development of novel antibody-drug conjugate therapeutics for the treatment of cancer, is an attractive investment, the analyst cited points to three primary factors: “the favorable outlook for [its lead candidate], the long-term potential of the biotech’s pipeline and the continuing validation, by partners, of its proprietary technology.” For more on the biotech in question and each of these factors making it an appealing pick, CLICK HERE.
Should You “Buy The Dip” In This Biotech With A Revolutionary Cancer Treatment?
The biotech stock that’s the focus of today’s article recently dipped after reporting clinical trial results for its revolutionary cancer treatment “that were positive but perhaps not positive enough to outrun the competition.” So could it represent a good “buy the dip” opportunity? The author outlines the reasons to consider buying this stock, as well as some reasons to exercise caution. For more, CLICK HERE.
Young Monsters: 2 Biotech Stocks To Watch
In regards to the two relatively young biotech stocks with monster potential discussed in today’s article, the author has the following to say: “…they have deeply compelling projects that aim to cure or fully mitigate a handful of different medical conditions that were once considered intractable. Both have demonstrated excellent progress so far, not to mention financial strength. It’ll take them some time to proceed with clinical trials and eventually pull through for shareholders, but when they do, the rewards could be enormous.” For more, CLICK HERE.
4 Biotech Stocks To Buy, According To UBS
UBS just initiated coverage on nine biotech stocks, four of which its analysts have given ‘Buy’ ratings – and two of those, the analysts believe, could soar by more than 50%. For these four biotech stocks that investors should buy, according to UBS, as well as the five biotech stocks that the firm initiated coverage on at a ‘Neutral’ rating, CLICK HERE.
